Adcirca Related Published Studies
Well-designed clinical trials related to Adcirca (Tadalafil)
Urodynamic effects of the combination of tamsulosin and daily tadalafil in men
with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a
randomized, placebo-controlled clinical trial. [2013]
The role of initial success rates and other factors in determining reliability of
outcomes of phosphodiesterase inhibitor therapy for erectile dysfunction: a
pooled analysis of 17 placebo-controlled trials of tadalafil for use as needed. [2013]
Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. [2011.11.15]
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. [2011.11]
Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study. [2011.09]
Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study. [2011.07]
Oral tadalafil administration plus low dose vasodilator injection: a novel approach to erection induction for penile color duplex ultrasound. [2011.07]
[Efficacy and safety of long-term small-dose tadalafil in the treatment of erectile dysfunction]. [2011.06]
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. [2011.06]
Efficacy and tolerability of tadalafil for treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. [2011.05]
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. [2011.04]
Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. [2011.03]
Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. [2011.01]
Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). [2011.01]
Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. [2010.12]
Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. [2010.10]
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. [2010.06]
Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. [2010.06]
Tadalafil: in pulmonary arterial hypertension. [2010.03.05]
Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. [2010.03]
Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. [2010.03]
Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. [2010.02]
Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success. [2010.01]
Impact of tadalafil once daily in men with erectile dysfunction--including a
report of the partners' evaluation. [2010]
Tadalafil: in pulmonary arterial hypertension. [2010]
Urodynamic effects of once daily tadalafil in men with lower urinary tract
symptoms secondary to clinical benign prostatic hyperplasia: a randomized,
placebo controlled 12-week clinical trial. [2010]
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. [2009.12]
[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil] [2009.11]
Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis. [2009.10]
Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. [2009.10]
[Chronic PDE-5 inhibition in patients with erectile dysfunction : New treatment approach using once daily Tadalafil.] [2009.09.09]
Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema. [2009.08.15]
Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. [2009.07]
Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. [2009.07]
Tadalafil therapy for pulmonary arterial hypertension. [2009.06.09]
Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. [2009.05]
Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia. [2009.04.22]
Retinal effects of 6 months of daily use of tadalafil or sildenafil. [2009.04]
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. [2009.02]
Effect of tadalafil on blood flow, pain, and function in chronic cold Complex Regional Pain Syndrome: a randomized controlled trial. [2008.10.20]
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. [2008.10]
Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. [2008.09]
Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. [2008.09]
Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: results of integrated analyses. [2008.08]
Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study. [2008.05]
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. [2008.05]
An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. [2008.05]
Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. [2008.02]
Effect of tadalafil on anaerobic performance indices in healthy athletes. [2008.02]
Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. [2008.01]
Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. [2008]
Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. [2007.12]
Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury. [2007.11]
Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. [2007.10]
Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men. [2007.10]
Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension. [2007.07]
Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. [2007.07]
Tadalafil population pharmacokinetics in patients with erectile dysfunction. [2007.06]
Evaluation of an alternative dosing regimen with tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy. [2007.05]
A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction. [2007.05]
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. [2007.04]
The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. [2007.04]
Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. [2007.03]
The influence of age on treatment outcomes in men with erectile dysfunction treated with two regimens of tadalafil: results of the SURE study. [2007.01]
Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. [2007.01]
Well-designed clinical trials possibly related to Adcirca (Tadalafil)
Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients
with end-stage renal disease receiving dialysis or after renal transplantation. [2013]
Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. [2011.11]
Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. [2011.06.15]
Effect on sexual function of a vacuum erection device post-prostatectomy. [2011.06]
Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. [2011.06]
The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. [2011.04]
The effects of phosphodiesterase type 5 inhibitors on penile rigidity variables during a period with no sexual stimulation: a laboratory setting double-blind study. [2011.01]
Minimal clinically important differences in the erectile function domain of the
International Index of Erectile Function scale. [2011]
Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors. [2010.01]
Randomized, placebo-controlled, double-blind, parallel design trial of the efficacy and safety of Zestra in women with mixed desire/interest/arousal/orgasm disorders. [2010]
Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. [2009.11.03]
Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis. [2009.10.19]
Prospective pharmacologic therapies for the overactive bladder. [2009.06]
Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome. [2009.05]
Treatment of erectile dysfunction reduces psychological distress. [2009.02]
Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach. [2009.01]
Erectile dysfunction after therapy with metoprolol: the hawthorne effect. [2009]
Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. [2008.01]
Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. [2008.01]
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition. [2008]
Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction. [2007.08]
Other research related to Adcirca (Tadalafil)
Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily
for lower urinary tract symptoms secondary to benign prostatic hyperplasia:
analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. [2015]
Effects of tadalafil once daily on maximum urinary flow rate in men with lower
urinary tract symptoms suggestive of benign prostatic hyperplasia. [2014]
Regional cerebral blood flow following single-dose and continuous-dose tadalafil
after stroke. [2014]
Tadalafil in patients with chronic obstructive pulmonary disease: a randomised,
double-blind, parallel-group, placebo-controlled trial. [2014]
[On-demand versus on-time dosing of tadalafil for erectile dysfunction: a
prospective multi-center study]. [Article in Chinese] [2014]
[Safety and efficacy of L-carnitine and tadalafil for late-onset hypogonadism
with ED: a randomized controlled multicenter clinical trial]. [Article in Chinese] [2014]
[Low-dose testosterone undecanoate capsules combined with tadalafil for
late-onset hypogonadism accompanied with ED]. [Article in Chinese] [2013]
Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms
secondary to benign prostatic hyperplasia: a meta-analysis. [2013]
[Low-dose daily de-escalatory administration of tadalafil for psychological
erectile dysfunction]. [Article in Chinese] [2013]
Tadalafil once daily for lower urinary tract symptoms suggestive of benign
prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week
study in Asian men. [2013]
Analysis of the therapeutic effect of tadalafil on male ED after transurethral
resection of prostate. [2012]
Tadalafil once daily and extracorporeal shock wave therapy in the management of
patients with Peyronie's disease and erectile dysfunction: results from a
prospective randomized trial. [2012]
Endothelial antioxidant compound prolonged the endothelial antiapoptotic effects
registered after tadalafil treatment in patients with arterial erectile
dysfunction. [2012]
Tadalafil 2.5 or 5 mg Administered Once Daily for 12 Weeks in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia: Results of a Randomized, Placebo-Controlled, Double-Blind Study. [2011.10.07]
Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil. [2011.02]
|